why choose us

First received: October 13, 2022

Clinical Trial: Phase 2b Study of GSK4532990 in Adults With NASH

Study Status: Completed

Recruit Status: RECRUITING

Condition: Nonalcoholic Fatty Liver Disease

Study Type: INTERVENTIONAL


Official Title: 17 ?-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adult

Brief Summary: The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced (F3) fibrosis.The study duration will be up to 76 weeks including the screening period.The treatment duration will be up to 52 weeks.

Read more